Janna Baez

Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM

Yu Akahoshi, Nikolaos Katsivelos, Ioannis E Louloudis, Daniela Weber et autres

= .026). MAGIC biomarkers identified most patients with grade I GVHD as low risk and unlikely to progress to severe GVHD regardless of treatment. Nevertheless, low-risk patients who received up-front steroids experienced a threefold increase in infectious deaths compared with those treated …

us, de, th, it (code pays fourni par la source)

Grade I acute graft-vs-host disease: Treat or not?

Yu Akahoshi, Nikolaos Katsivelos, Ioannis Evangelos Louloudis, Daniela Weber et autres

Abstract Background Acute graft-versus-host disease (GVHD) is a major cause of non-relapse mortality (NRM) after allogeneic hematopoietic cell transplantation (HCT). High-dose steroids are standard first-line therapy for grade II–IV acute GVHD, whereas systemic treatment (tx) is generally not recommended for grade I. …

us, de, ch, th, it (code pays fourni par la source)

Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity

Ioannis Evangelos Louloudis, Nikolaos Spyrou, Amin Alousi, Nikolaos Katsivelos et autres

us, de, th, it, ca (code pays fourni par la source)

The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD

Yu Akahoshi, Joseph Portelli, Nikolaos Katsivelos, Ioannis Evangelos Louloudis et autres

ABSTRACT: Changes in the clinical symptoms of acute graft-versus-host disease (GVHD) are currently used to assess treatment responses. The Mount Sinai Acute GVHD International Consortium (MAGIC) consortium has recently revealed that the integration of serum biomarkers with clinical symptoms at the onset …

us, de, th, it, ca, nz (code pays fourni par la source)

Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group

Nikolaos Katsivelos, Nikolaos Spyrou, Daniela Weber, Ingrid Vášová et autres

BACKGROUND: The standard treatment for acute graft-vs-host disease (GVHD), a common complication following allogeneic hematopoietic cell transplant, remains prolonged courses of high dose corticosteroids. Previous attempts to decrease corticosteroid exposure during GVHD therapy failed because physicians lack the tools necessary to safely …

us, de, ca, th, it (code pays fourni par la source)

Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd

Nikolaos Katsivelos, Nikolaos Spyrou, Daniela Weber, Ingrid Vášová et autres

Background: The majority of patients respond to steroid treatment for graft-vs-host disease (GVHD), but the typically high doses and prolonged courses can cause substantial morbidity. GVHD can be classified at onset into two groups with significant differences in treatment response and non-relapse …

us, de, ca, th, it, jp (code pays fourni par la source)

Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients

Carlos A. Ortega Rios, Muna Qayed, Aaron M. Etra, Ran Reshef et autres

Acute graft-versus-host disease (GVHD) is a significant complication following hematopoietic stem cell transplantation (HCT). Although recent advancements in GVHD prophylaxis have resulted in successful HCT across HLA barriers and expanded access to HCT for racial minorities, less is known about how race …

us, it, de (code pays fourni par la source)

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

Yu Akahoshi, Nikolaos Spyrou, Daniela Weber, Paibel Ixia Aguayo-Hiraldo et autres

ABSTRACT: Acute graft-versus-host disease (GVHD) grading systems that use only clinical symptoms at treatment initiation such as the Minnesota risk identify standard and high-risk categories but lack a low-risk category suitable to minimize immunosuppressive strategies. We developed a new grading system that …

us, de, th, it, ca (code pays fourni par la source)

The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD

Zachariah Michael DeFilipp, Haesook T. Kim, Nikolaos Spyrou, Nikolaos Katsivelos et autres

ABSTRACT: The significance of biomarkers in second-line treatment for acute graft-versus-host disease (GVHD) has not been well characterized. We analyzed clinical data and serum samples at the initiation of second-line systemic treatment of acute GVHD from 167 patients from 17 centers of …

us, de (code pays fourni par la source)

Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD

Aaron M. Etra, Najla El Jurdi, Nikolaos Katsivelos, Deukwoo Kwon et autres

ABSTRACT: Graft-versus-host disease (GVHD) is a major cause of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation. Algorithms containing either the gastrointestinal (GI) GVHD biomarker amphiregulin (AREG) or a combination of 2 GI GVHD biomarkers (suppressor of tumorigenicity-2 [ST2] + regenerating family …

us, de, th, it, ca (code pays fourni par la source)

A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD

Muna Qayed, Urvi Kapoor, Scott E. Gillespie, Adrianna Lynn Westbrook et autres

Acute graft versus host disease (GVHD) is a common and serious complication of allogeneic hematopoietic cell transplantation (HCT) in children but overall clinical grade at onset only modestly predicts response to treatment and survival outcomes. Two tools to assess risk at initiation …

us, de, it, ca (code pays fourni par la source)

Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis

Yu Akahoshi, Nikolaos Spyrou, Matthias Hoepting, Paibel Ixia Aguayo-Hiraldo et autres

ABSTRACT: The absence of a standardized definition for graft-versus-host disease (GVHD) flares and data on its clinical course are significant concerns. We retrospectively evaluated 968 patients across 23 Mount Sinai Acute GVHD International Consortium (MAGIC) transplant centers who achieved complete response (CR) …

jp, us, de, th, it, ca (code pays fourni par la source)